Baird upgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Neutral to Outperform. Raises PT from $12 to $14.

Baird analyst says, "Completion ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE